Titan Pharmaceuticals Report issue

For profit Phase 2 Phase 3
Founded: South San Francisco CA United States (1992)
Status: Left NME R&D (2022)

Organization Overview

First Clinical Trial
2000
NCT00761436
First Marketed Drug
2016
buprenorphine
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Alternative names

Titan Pharmaceuticals | TITAN PHARMS

Active Ingredients

Marketed Drugs (1)

buprenorphine (2016)

Drugs in Phase 3 Trials (1)

buprenorphine (2 trials)

Drugs in Phase 2 Trials (6)

Diiodothyropropionic acid (1 trial)

docetaxel (taxotere) (1 trial)

gallium maltolate (1 trial)

pivanex (3 trials)

ropinirole (Requip) (1 trial)

spheramine (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Behavior, Addictive (Phase 3)

Carcinoma (Phase 2)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Heart Failure (Phase 2)

Leukemia (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Melanoma (Phase 2)

Multiple Myeloma (Phase 2)

Neoplasms (Phase 2)

Opioid-Related Disorders (Phase 3)

Parkinson Disease (Phase 2)

Prostatic Neoplasms (Phase 2)

Urinary Bladder Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 10
  • # of Trial APIs: 7